ARTIDIS announces publication demonstrating the nanomechanical signature of response to low-dose radiotherapy followed by CAR T cell therapy in solid tumors.

Back to Home
08

Nov 2024

ARTIDIS announces publication demonstrating the nanomechanical signature of response to low-dose radiotherapy followed by CAR T cell therapy in solid tumors.

ARTIDIS logo
Press 0 Comments

Read more
24

Sep 2024

Former U.S. CDC Director joins Board of Swiss health technology company: ARTIDIS announces board appointment of Dr. Julie Gerberding, President and CEO of the U.S. Foundation for the National Institutes of Health (FNIH)

ARTIDIS logo
Press 0 Comments

Read more
02

Nov 2023

ARTIDIS Launches Groundbreaking ANGEL Study: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient’s Bedside with Over 2,700 Participants

ARTIDIS logo
Press 0 Comments

Read more
13

Feb 2023

ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors

team_members_ajit_400x400
Press 0 Comments

Read more
03

Oct 2022

MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment

md_anderson--artidis
Press 0 Comments

Read more
04

May 2021

“I like a good challenge” – Dr. Marija Plodinec about ARTIDIS in Basel Area Business & Innovation podcast

marijaplodinec-audio_post-600x600
Press 0 Comments

Read more
04

May 2021

ARTIDIS enters clinical collaboration to investigate nanomechanical profiling as a novel diagnostic and treatment optimization approach in patients with lung cancer

ARTIDIS logo
Press 0 Comments

Read more
21

Dec 2020

ARTIDIS investigates nanomechanical tissue signature to improve response to radio/immuno-therapy in lung cancer

ARTIDIS logo
Press 0 Comments

Read more
22

Jun 2020

ARTIDIS First Prospective Study, “NANO”, Evaluating its Nanotechnology Platform Based on a Novel Nanomechanical Biomarker in Breast Cancer Meets Primary Endpoint

img_news_artidisC_darker
Press 0 Comments

Basel, Switzerland, June 22, 2020 – ARTIDIS AG, a clinical stage health-tech company, announced today that its proprietary nanotechnology platform for cancer diagnosis has met the primary endpoint in the “NANO” clinical study.

Read more
24

Jan 2020

Dr. Marija Plodinec about ARTIDIS with Alec Santiago – podcast in two parts

img_news_artidis2A
Press 0 Comments

Our CEO Dr. Marija Plodinec explains what ARTIDIS is all about in a very interesting and inspiring conversation with Alec Santiago. Part one:   Part two:

Read more